{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:31:14Z","timestamp":1793331074414,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec id=\"ab-eoi250049-4\"><jats:title>Importance<\/jats:title><jats:p>Myopia is a global health concern, with high myopia elevating the risk of ocular complications. While atropine can affect myopia progression, its long-term safety profile remains uncertain.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250049-5\"><jats:title>Objective<\/jats:title><jats:p>To investigate the ocular risks associated with atropine prescription in clinical practice for myopia control in Taiwanese children.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250049-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a retrospective, population-based cohort study using longitudinal data from Taiwan\u2019s National Health Insurance Research Database (2000-2021). Children aged 8 to 15 years with newly diagnosed myopia and matched nonmyopic control participants in the period between 2001 and 2015 were included. Data analysis was performed from March 8 to May 30, 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250049-7\"><jats:title>Exposure<\/jats:title><jats:p>Data on atropine prescription were collected, and participants were categorized by cumulative duration and dose.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250049-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Diagnoses of cataracts, primary open-angle glaucoma, and maculopathy were recorded during the observation period. The incidence of ocular complications after a minimum 5-year follow-up period was reported. Hazard ratios (HRs) were derived using multivariable Cox regression models to evaluate atropine-related risks.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250049-9\"><jats:title>Results<\/jats:title><jats:p>A total of 1\u202f213\u202f846 Taiwanese children (mean [SD] age at myopia diagnosis, 10.4 [1.9] years; 633\u202f440 [52.2%] female) were included. Among 606\u202f923 children with myopia, 406\u202f383 (67.0%) were prescribed atropine. The incidence of ocular complications (cataracts, glaucoma, and maculopathy) was higher in the myopia group (1.54 per 10\u202f000 person-years) compared with the nonmyopia group (0.96 per 10\u202f000 person-years; adjusted HR [aHR], 1.49; 95% CI, 1.36-1.64). In children with myopia, the incidence of ocular complications was not different between atropine users and nonusers (both 1.54 per 10\u202f000 person-year; aHR, 1.05; 95% CI, 0.93-1.18). An increased risk of ocular complications was observed in children with cumulative duration of atropine prescription exceeding 3 years (aHR, 1.51; 95% CI, 1.17-1.94). However, this trend was not present when conditioned on children with high myopia (aHR, 1.10; 95% CI, 0.56-2.19). No increased risk was found among children with the highest quartile of cumulative atropine dose (aHR, 1.05; 95% CI, 0.89-1.25).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250049-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>While the incidence of cataracts, glaucoma, or maculopathy was higher in children with myopia, atropine prescription was not associated with these risks. While these findings offer insights for weighing risks and benefits of atropine use in myopia control, they are limited to atropine prescriptions implying atropine use, and they generate hypotheses but cannot imply cause-and-effect relationships.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.3090","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:00:40Z","timestamp":1757602840000},"page":"855","source":"Crossref","is-referenced-by-count":5,"title":["Ocular Risks of Topical Atropine Prescriptions Among Taiwanese Children"],"prefix":"10.1001","volume":"143","author":[{"given":"Yao-Lin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yu","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yen","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ju","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian G.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Research School of Biology, Australian National University, Canberra, Australian Capital Territory, Australia"},{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsun","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Ophthalmology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"eoi250049r1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050.","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi250049r2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis.","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"eoi250049r3","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1097\/IAE.0000000000001489","article-title":"Overview of the complications of high myopia.","volume":"37","author":"Ikuno","year":"2017","journal-title":"Retina"},{"issue":"5","key":"eoi250049r4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications.","volume":"25","author":"Saw","year":"2005","journal-title":"Ophthalmic Physiol Opt"},{"issue":"11","key":"eoi250049r5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","article-title":"The risks and benefits of myopia control.","volume":"128","author":"Bullimore","year":"2021","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi250049r6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/OPX.0000000000001367","article-title":"Myopia control: why each diopter matters.","volume":"96","author":"Bullimore","year":"2019","journal-title":"Optom Vis Sci"},{"issue":"1","key":"eoi250049r7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.1999.15.85","article-title":"Effects of different concentrations of atropine on controlling myopia in myopic children.","volume":"15","author":"Shih","year":"1999","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"eoi250049r8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia.","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi250049r9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi250049r10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on Atropine for the Treatment of Myopia 2: myopia control with atropine 0.01% eyedrops.","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi250049r11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial.","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"eoi250049r12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial.","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"eoi250049r13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","article-title":"Five-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: phase 4 report.","volume":"131","author":"Zhang","year":"2024","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi250049r14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamaophthalmol.2024.5703","article-title":"Efficacy and safety of different atropine regimens for the treatment of myopia in children: three-year results of the MOSAIC randomized clinical trial.","volume":"143","author":"Loughman","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"eoi250049r15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/eye.2012.279","article-title":"Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study.","volume":"27","author":"Fang","year":"2013","journal-title":"Eye (Lond)"},{"issue":"6","key":"eoi250049r16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1034\/j.1600-0420.2001.790603.x","article-title":"Refractive error and glaucoma.","volume":"79","author":"Gr\u00f8dum","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"eoi250049r17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/jop.2017.0144","article-title":"A review of myopia control with atropine.","volume":"34","author":"Tran","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"eoi250049r18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis.","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"eoi250049r19","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/jcm13113218","article-title":"Efficacy and safety of 0.03% atropine eye drops in controlling myopia progression: a one-year prospective clinical study.","volume":"13","author":"Simonaviciute","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"eoi250049r20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ophtha.2020.07.017","article-title":"Evolution of the prevalence of myopia among Taiwanese schoolchildren: a review of survey data from 1983 through 2017.","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi250049r21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004916.pub4","article-title":"Interventions to slow progression of myopia in children.","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"eoi250049r22","first-page":"180","article-title":"Comparison of the effect of atropine and cyclopentolate on myopia.","volume":"21","author":"Yen","year":"1989","journal-title":"Ann Ophthalmol"},{"issue":"4","key":"eoi250049r23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.13.4.22","article-title":"Differential impact of 0.01% and 0.05% atropine eyedrops on ocular surface in young adults.","volume":"13","author":"Luo","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"eoi250049r24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1034\/j.1600-0420.2001.790304.x","article-title":"An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression.","volume":"79","author":"Shih","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"issue":"1","key":"eoi250049r25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12886-016-0297-y","article-title":"Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study.","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"eoi250049r26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4103\/tjo.TJO-D-24-00026","article-title":"Impact of atropine use for myopia control on intraocular pressure in children: a comprehensive review including postpupil dilation intraocular pressure changes.","volume":"14","author":"Chen","year":"2024","journal-title":"Taiwan J Ophthalmol"},{"issue":"3","key":"eoi250049r27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi250049r28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","article-title":"Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology.","volume":"124","author":"Pineles","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi250049r29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.","volume":"157","author":"Chia","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi250049r30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/ICL.0b013e31821cbcc9","article-title":"Ultraviolet radiation as a risk factor for cataract and macular degeneration.","volume":"37","author":"Roberts","year":"2011","journal-title":"Eye Contact Lens"},{"issue":"22","key":"eoi250049r31","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198812013192201","article-title":"Effect of ultraviolet radiation on cataract formation.","volume":"319","author":"Taylor","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi250049r32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamaophthalmol.2023.5467","article-title":"Topical atropine for childhood myopia control: the Atropine Treatment Long-Term Assessment Study.","volume":"142","author":"Li","year":"2024","journal-title":"JAMA Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2838641\/jamaophthalmology_liu_2025_oi_250049_1759774123.24306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:01:42Z","timestamp":1760626902000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2838641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.3090","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}